Therapeutic decisions for menopause: Results of the DAMES project in central Massachusetts

Menopause

Volumn 11, Issue 4, 2004, Pages 456-465

  Obermeyer, Carla Makhlouf ^a   Reynolds, Robert F ^b   Price, Kim ^a   Abraham, Annie ^c  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b PFIZER INC   (United States)

^c Fallon Clinic   (United States)

Author keywords

Consultation; Hormone therapy; Massachusetts; Menopause symptoms; Perimenopause

Indexed keywords

ADULT; ARTICLE; DECISION MAKING; ESTROGEN THERAPY; FEMALE; HEALTH STATUS; HEALTH SURVEY; HORMONAL THERAPY; HOT FLUSH; HUMAN; INTERVIEW; LIFESTYLE; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; MENOPAUSE; SYMPTOMATOLOGY; UNITED STATES; CLIMACTERIUM; HEART RATE; MIDDLE AGED; MULTICENTER STUDY; POSTMENOPAUSE; SLEEP DISORDER; WOMEN'S HEALTH;

ADULT; CLIMACTERIC; DECISION MAKING; FEMALE; HEALTH SURVEYS; HEART RATE; HOT FLASHES; HUMANS; LIFE STYLE; MASSACHUSETTS; MENOPAUSE; MIDDLE AGED; MULTICENTER STUDIES; POSTMENOPAUSE; SLEEP DISORDERS; WOMEN'S HEALTH;

EID: 4644299701     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.GME.0000109318.11228.DA     Document Type: Article

References (69)

1. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288:49-57.
2. Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288:58-66.
3. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
4. Bergkvist L, Adami HO, Persson I, Hoover R, Schairer C. The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 1989;321:293-7.
5. Barrett-Connor E, Wingard DL, Criqui MH. Postmenopausal estrogen use and heart disease risk factors in the 1980s. Rancho Bernardo, Calif, revisited. JAMA 1989;261:2095-100.
6. Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 1998; 19: 55-72.
7. Stanford JL, Weiss NS, Voigt LF, Daling JR, Habel LA, Rossing MA. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 1995;274:137-42.
8. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N Engl J Med 1991;325:756-62.
9. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-37.
10. Archer D. Hormone replacement therapy and the risk of breast cancer: the continuing controversy. Menopause 1996;3:1-2.
11. Ewertz M. Hormone therapy in the menopause and breast cancer risk-a review. Maturitas 1996;23:241-6.
12. Brinton LA, Schairer C. Postmenopausal hormone-replacement therapy-time for a reappraisal? N Engl J Med 1997;336:1821-2.
13. Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996;335:453-61.
14. Hemminki E, McPherson K. Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials. BMJ 1997;315:149-53.
15. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13.
16. Petitti DB. Hormone replacement therapy and heart disease prevention: experimentation trumps observation. JAMA 1998;280:650-2.
17. Obermeyer CM. Menopause across cultures: a review of the evidence. Menopause 2000;7:184-92.
18. Spetz A-CE, Fredriksson MG, Hammar ML. Hot flushes in a male population aged 55, 65, and 75 years, living in the community of Linköping, Sweden. Menopause 2003;10:81-7.
19. VanHall E, Verdel M, Van der Velden J. 'Perimenopausal' complaints in women and men: a comparative study. J Womens Health 1994;3:45-9.
20. Calvaresi E, Bryan J. Symptom experience in Australian men and women in midlife. Maturitas 2003;44:225-36.
21. McKinlay SM, Brambilla DJ, Posner JG. The normal menopause transition. Maturitas 1992;14:103-15.
22. Avis NE, Kaufert PA, Lock M, McKinlay SM, Vass K. The evolution of menopausal symptoms. Baillieres Clin Endocrinol Metab 1993;7:17-32.
23. Oddens BJ, Boulet MJ, Lehert P, Visser AP. Has the climacteric been medicalized? A study on the use of medication for climacteric complaints in four countries. Maturitas 1992;15:171-81.
24. Bardel A, Wallander MA, Svardsudd K. Hormone replacement therapy and symptom reporting in menopausal women: a population-based study of 35- to 65-year-old women in mid-Sweden. Maturitas 2002;41:7-15.
25. Chim H, Tan BH, Ang CC, Chew EM, Chong YS, Saw SM. The prevalence of menopausal symptoms in a community in Singapore. Maturitas 2002;41:275-82.
26. Leung TN, Haines CJ, Chung TK. Five-year compliance with hormone replacement therapy in postmenopausal Chinese women in Hong Kong. Maturitas 2001;39:195-201.
27. Harlow SD, Crawford SL, Sommer B, Greendale GA. Self-defined menopausal status in a multi-ethnic sample of midlife women. Maturitas 2000;36:93-112.
28. Kravitz HM, Ganz PA, Bromberger J, Powell LH, Sutton-Tyrrell K, Meyer PM. Sleep difficulty in women at midlife: a community survey of sleep and the menopausal transition. Menopause 2003; 10: 19-28.
29. Mingo C, Herman CJ, Jasperse M. Women's stories: ethnic variations in women's attitudes and experiences of menopause, hysterectomy, and hormone replacement therapy. J Womens Health Gend Based Med 2000;9(Suppl 2):S27-38.
30. Schneider HP, Heinemann LA, Rosemeier HP, Potthoff P, Behre HM. The Menopause Rating Scale (MRS): reliability of scores of menopausal complaints. Climacteric 2000;3:59-64.
31. Strickland OL, Dunbar SB. The perceptions of menopause of African-American and white women and affect on willingness to participate in a HRT clinical trial. J Natl Black Nurses Assoc 2000;11: 43-50.
32. Sternfeld B, Cauley J, Harlow S, Liu G, Lee M. Assessment of physical activity with a single global question in a large, multiethnic sample of midlife women. Am J Epidemiol 2000;152:678-87.
33. Bosworth HB, Bastian LA, Kuchibhatla MN, et al. Depressive symptoms, menopausal status, and climacteric symptoms in women at midlife. Psychosom Med 2001;63:603-8.
34. von Muhlen DG, Kritz-Silverstein D, Barrett-Connor E. A community-based study of menopause symptoms and estrogen replacement in older women. Maturitas 1995;22:71-8.
35. Kam IW, Dennehy CE, Tsourounis C. Dietary supplement use among menopausal women attending a San Francisco health conference. Menopause 2002;9:72-8.
36. Avis NE, McKinlay SM. A longitudinal analysis of women's attitudes toward the menopause: results from the Massachusetts Women's Health Study. Maturitas 1991;13:65-79.
37. McKinlay JB, McKinlay SM, Brambilla DJ. Health status and utilization behavior associated with menopause. Am J Epidemiol 1987; 125:110-21.
38. Johannes CB, Crawford SL, Posner JG, McKinlay SM. Longitudinal patterns and correlates of hormone replacement therapy use in middle-aged women. Am J Epidemiol 1994;140:439-52.
39. McKinlay S, McKinlay J. Health status and health care utilization by menopausal women. In: Mastroianni L, Paulsenn C, eds. Aging, Reproduction, and the Climacteric. New York: Plenum Press; 1984:243-62.
40. McKinlay SM, Bifano NL, McKinlay JB. Smoking and age at menopause in women. Ann Intern Med 1985;103:350-6.
41. Reynolds RF, Obermeyer CM. Correlates of the age at natural menopause in Morocco. Ann Hum Biol 2003;30:97-108.
42. Reynolds RF, Obermeyer CM, Walker AM, Guilbert D. The role of treatment intentions and concerns about side effects in women's decision to discontinue postmenopausal hormone therapy. Maturitas 2002;43:183-94.
43. Obermeyer CM, Ghorayeb F, Reynolds R. Symptom reporting around the menopause in Beirut, Lebanon. Maturitas 1999;33:249-58.
44. Obermeyer CM, Sahel A, Hajji N, Schulein M. Physicians' perceptions of menopause and prescribing practices in Morocco. Int J Gynaecol Obstet 2001;73:47-55.
45. Obermeyer CM, Schulein M, Hajji N, Azelmat M. Menopause in Morocco: symptomatology and medical management. Maturitas 2002;41:87-95.
46. Kaufert P, Syrotuick J. Symptom reporting at the menopause. Soc Sci Med 1981;22:173-84.
47. Sarrel L, Sarrel P. Helping women decide about hormone replacement therapy: approaches to counselling and medical practices. In: Berg G, Hammar M, eds. The Modern Management of Menopause. New York: Parthenon Publishing Group; 1994:499-509.
48. Boulet MJ, Oddens BJ, Lehert P, Vemer HM, Visser A. Climacteric and menopause in seven Southeast Asian countries. Maturitas 1994;19:157-76.
49. Kaufert P, Lock M, McKinlay S, et al. Menopause research: the Korpilampi workshop. Soc Sci Med 1986;22:1285-9.
50. Lock M. Encounters with Aging: Mythologies of Menopause in Japan and North America. Berkeley: University of California Press, 1993.
51. N6 [computer program]. Version 6.0. Non-numerical Unstructured Data Indexing, Searching and Theorizing, qualitative data analysis program. Melbourne, Australia: QSR International Pty Ltd.; 2002.
52. United States Census Bureau: United States Census 2000. Available at: http://www.census.gov/main/www/cen2000.html. Accessed January 2003.
53. Leidy LE, Canali C, Callahan WE. The medicalization of menopause: implications for recruitment of study participants. Menopause 2000;7:193-9.
54. Boraz MA, Simkin-Silverman LR, Wing RR, Meilahn EN, Kuller LH. Hormone replacement therapy use and menopausal symptoms among women participating in a behavioral lifestyle intervention. Prev Med 2001;33:108-14.
55. Avis NE, Stellate R, Crawford S, et al. Is there a menopausal syndrome? Menopausal status and symptoms across racial/ethnic groups. Soc Sci Med 2001;52:345-56.
56. Grizzo JA, Freeman E, Maurin E, Garcia-Espana B, Berlin J. Racial differences in menopause information and the experience of hot flashes. J Gen Intern Med 1999;14:98-103.
57. Avis NE, Crawford S, Stellate R, Longcope C. Longitudinal study of hormone levels and depression among women transitioning through menopause. Climacteric 2001;4:243-9.
58. Johansson SR. The health transition: the cultural inflation of morbidity during the decline of mortality. Health Transit Rev 1991;1: 39-65.
59. Murray CJL, Chen LC. Understanding morbidity change. Popul Dev Rev 1992;18:481-503.
60. Harris RB, Laws A, Reddy VM, King A, Haskell WL. Are women using postmenopausal estrogens? A community survey. Am J Public Health 1990;80:1266-8.
61. Derby C, Hume A, Barbour MM, McPhillips J, Lasater T, Caleton R. Correlates of postmenopausal estrogen use and trends through the 1980s in two southeastern New England communities. Am J Epidemiol 1993;137:1125-35.
62. Brett K, Madans J. Differences in use of postmenopausal hormone replacement therapy by black and white women. Menopause 1997; 4:66-70.
63. Keating NL, Cleary PD, Rossi AS, Zaslavsky AM, Ayanian JZ. Use of hormone replacement therapy by postmenopausal women in the United States. Ann Intern Med 1999;130:545-53.
64. Barrett-Connor E. Prevalence, initiation, and continuation of hormone replacement therapy. J Womens Health 1995;4:143-8.
65. Utian W, Schiff I. NAMS-Gallup survey on women's knowledge, information sources, and attitudes towards menopause and hormone replacement therapy. Menopause 1994;1:39-48.
66. Reynolds RF, Walker AM, Obermeyer CM, Rahman O, Guilbert D. Discontinuation of postmenopausal hormone therapy in a Massachusetts HMO. J Clin Epidemiol 2001;54:1056-64.
67. Massey JT, O'Connor D, Krotki K. Response rates in random digit dialing (RDD) telephone surveys. Paper presented at: Proceedings of the Survey Research Methods Section, American Statistical Association, 1997, Anaheim, CA.
68. Reynolds RF, Obermeyer CM, Walker AM, Guilbert D. Side effects and sociobehavioral factors associated with the discontinuation of hormone therapy in a Massachusetts health maintenance organization. Menopause 2001;8:189-99.
69. Morrissey J. HMOs rule in Boston market. But costs, utilization are high. Mod Healthc 1998;28:56-58, 60-52, 64-55.